The concentration of tumor necrosis factor alpha in plasma of patients with hyperlipoproteinaemia IIb before and after micronized fenofibrate therapy;Stezenia czynnika martwicy nowotworow alfa w surowicy pacjentow z hiperlipoproteinemia IIb przed i po podjeciu terapii fenofibratem mikronizowanym

Polskie Archiwum Medycyny Wewnetrznej

Volumn 99, Issue 4, 1998, Pages 308-313

  Madej, Andrzej ^a   Okopień, Bogusław ^a   Kowalski, Jan ^a   Zieliński, Marek ^a   Wysocki, Janusz ^b   Szyguła, Bozena ^b   Kalina, Zbigniew ^b   Herman, Zbigniew S ^a  

^a Zak ad Farmakologii K   (Poland)

^b Kat i Klinika Chorob W   (Poland)

Author keywords

Fibrates; Hyperlipoproteinaemia IIb; Tumor necrosis factor alpha

Indexed keywords

CHOLESTEROL; FENOFIBRATE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ANTILIPEMIC AGENT; APOLIPOPROTEIN B;

ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE ACTIVATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; ARTERIOSCLEROSIS; BLOOD; DRUG FORMULATION; FEMALE; HYPERLIPOPROTEINEMIA TYPE 2; MALE; MIDDLE AGED;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; CHOLESTEROL; DRUG COMPOUNDING; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROCETOFEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032038136     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Davies M.J., Woolf N.: Atherosclerosis: What is it and why does it occur? Br. Heart J., 1993, 69, 3.
2. Ross R.: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993, 362, 801.
3. O'Brien K.D., Chait A.: The biology of the artery wall in atherogenesis. Lipid Disorders, 1994, 78, 41.
4. Ross R.: Polypeptide growth factors and atherosclerosis. Trends Cardiovasc. Med., 1991, 1, 277.
5. Anderson K.M., Castelli W.P., Levy D.: Cholesterol and Mortality: 30 years of follow-up from the Framingham Study. JAMA, 1987, 257, 2176.
6. Steinmetz A., Schwarte T., Henke U., Kaffarnik H.: Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipoprotenemia. J. Cardiovasc. Pharmacol., 1996, 27, 563.
7. Shepherd J.: Atherosclerosis, 1994, 110, 55.
8. Otto C., Ritter M.M., Soennichsen A.C., Schwandt P., Richter W.O.: Effect of n-3 fatty acid and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia. Metabolism, 1996, 45, 1305.
9. Al-Janadi B., Al-Balla S., Al-Dalaan A., Raziuddin S.: Cytokine profile in systemic lupus erythematosus, rheumathoid arthritis, and other rheumatic diseases. J. Clin. Immunol., 1993, 13, 58.
10. Knopp R.H., Brown W. V., Dujovne C.A. i wsp.: Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am. J. Med., 1987, 83, 50.
11. Thorne S.A., Abbot S.E., Stevens C.E. i wsp.: Modified low density lipoprotein and cytokines mediate monocyte adhesion to smoth muscle cells. Atherosclerosis, 1996, 127, 167.
12. van der Wall A.C., Das P.K., Tigges A.J. i wsp.: Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am. J. Pathol., 1992, 141, 1427.
13. Hajjar K.A., Hajjar D.P., Silverstein R.L., Nachman R.L.: Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J. Exp. Med., 1987, 166, 235.
14. Kishikawa H., Shimokama T., Watanabe T.: Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human athrogenesis. Virchows Arch. Pathol. Anat. Histopathol., 1993, 423, 433.
15. Tipping P.G., Hancock W.W.: Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am. J. Pathol., 1993, 142, 1721.
16. Witztum J.L., Steinberg D.: Role of oxidized LDL in atherogenesis. Br. Heart J., 1993, 69, 512.
17. Jovinge S., Ares M.P., Kallin B., Nilsson J: Human monocytes/macrophages release TNF-alpha in response to OX-LDL. Arterioscler. Thromb. Vase. Biol., 1996, 16, 1573.
18. Vaddi K., Nicolini F.A., Mehta P., Mehta J.L.: Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischaemic heart diseases. Circulation, 1994, 90, 694.
19. Okopień B., Herman Z.S.: Miażdżycowe uszkodzenie te(Combining ogonek sign)tnic u pacjentów z przewlekłymi zakażeniami - mechanizmy immunologiczne i ryzyko choroby wieńcowej. Pol. Arch. Med. Wewn., 1997, 97, 578.